B3GAT1 and chronic myelogenous leukemia, BCR-ABL1 positive: NKG2D haplotype also represents a candidate biomarker for the prediction of treatment-free remission, described currently in patients with CML treated by dasatinib, where patients with HNK1/HNK1 haplotype achieved molecular response faster than patients with other haplotypes (25).